- Home
- SFST vs EDIT Comparison
SFST vs EDIT Comparison
Compare SFST & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFST
- EDIT
- Stock Information
- Founded
- SFST 1999
- EDIT 2013
- Country
- SFST United States
- EDIT United States
- Employees
- SFST N/A
- EDIT N/A
- Industry
- SFST Major Banks
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SFST Finance
- EDIT Health Care
- Exchange
- SFST Nasdaq
- EDIT Nasdaq
- Market Cap
- SFST 335.4M
- EDIT 269.8M
- IPO Year
- SFST 1999
- EDIT 2016
- Fundamental
- Price
- SFST $41.82
- EDIT $3.65
- Analyst Decision
- SFST Buy
- EDIT Buy
- Analyst Count
- SFST 1
- EDIT 11
- Target Price
- SFST $51.00
- EDIT $4.56
- AVG Volume (30 Days)
- SFST 17.3K
- EDIT 3.2M
- Earning Date
- SFST 10-21-2025
- EDIT 10-31-2025
- Dividend Yield
- SFST N/A
- EDIT N/A
- EPS Growth
- SFST 58.48
- EDIT N/A
- EPS
- SFST 2.69
- EDIT N/A
- Revenue
- SFST $102,878,000.00
- EDIT $38,901,000.00
- Revenue This Year
- SFST $13.23
- EDIT N/A
- Revenue Next Year
- SFST $17.49
- EDIT N/A
- P/E Ratio
- SFST $15.80
- EDIT N/A
- Revenue Growth
- SFST 15.60
- EDIT N/A
- 52 Week Low
- SFST $29.14
- EDIT $0.91
- 52 Week High
- SFST $46.40
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- SFST 43.60
- EDIT 51.73
- Support Level
- SFST $40.90
- EDIT $3.48
- Resistance Level
- SFST $42.88
- EDIT $4.27
- Average True Range (ATR)
- SFST 0.96
- EDIT 0.38
- MACD
- SFST -0.12
- EDIT -0.06
- Stochastic Oscillator
- SFST 30.11
- EDIT 28.34
About SFST Southern First Bancshares Inc.
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.